Pfizer Gets Setback In Lipitor Patent Battle

Law360, New York (August 30, 2006, 12:00 AM EDT) -- Lending a boost to Ranbaxy Laboratories’ global crusade, a Norwegian court has denied Pfizer Inc.’s claim that the Indian drug maker has infringed two patents related to blockbuster cholesterol drug Lipitor.

On Wednesday, the Oslo City Court sided with Ranbaxy, ruling that the company was not guilty of infringing two of Pfizer’s four Norwegian patents covering the cholesterol treatment.

"This is a most important decision for Ranbaxy, as it significantly validates our position regarding the atorvastatin patents," said Jay Deshmukh, senior vice president, global intellectual property...
To view the full article, register now.